Literature DB >> 12038517

Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients.

L Zahed1, F H Mourad, R Alameddine, S Aoun, S Koussa, A Taher.   

Abstract

Beta-thalassemia requires life-long treatment, including regular blood transfusion and daily iron chelation by desferrioxamine, which places considerable burden on the social and psychological life of patients. It is expected that oral chelation therapy, which is easier to administer, would improve their psychosocial status. In this sutdy, interviews were conducted with a series of 44 patients recently placed on oral chelation therapy to evaluate their reactions to the new treatment. Eighty-six per cent of patients complied better with the oral chelation therapy. Fifty per cent of patients mentioned that relief from the desferrioxamine pump was the major improvement, while 47% felt psychologically better. Fifty per cent of patients noted improvements in their relationships, while 63% noted increased social activities. Evaluation of a larger sample of patients over a longer period of time is needed in order to confirm the favourable results obtained in this study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12038517     DOI: 10.1163/15685590160141369

Source DB:  PubMed          Journal:  Haematologia (Budap)        ISSN: 0017-6559


  3 in total

Review 1.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients.

Authors:  Adriana Ceci; Laura Mangiarini; Mariagrazia Felisi; Franco Bartoloni; Angela Ciancio; Marcello Capra; Domenico D'Ascola; Paolo Cianciulli; Aldo Filosa
Journal:  Anemia       Date:  2011-06-05

3.  A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia.

Authors:  Paavani S Reddy; Margaret Locke; Sherif M Badawy
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.